{"api_version": 1, "episode_id": "ep_radiolab_fffeae512456", "title": "Worth", "podcast": "Radiolab", "podcast_slug": "radiolab", "category": "health", "publish_date": "2014-12-23T17:00:00+00:00", "audio_url": "https://pscrb.fm/rss/p/mgln.ai/e/14/prfx.byspotify.com/e/dts.podtrac.com/pts/redirect.mp3/waaa.wnyc.org/758af4c0-a2c3-47ec-a2d8-05f41bfbde51/episodes/b77b0536-9772-4ade-afca-d30de75d9f1b/audio/128/default.mp3?aid=rss_feed&awCollectionId=758af4c0-a2c3-47ec-a2d8-05f41bfbde51&awEpisodeId=b77b0536-9772-4ade-afca-d30de75d9f1b&feed=EmVW7VGp", "source_link": "https://www.radiolab.org", "cover_image_url": "https://image.simplecastcdn.com/images/758af4/758af4c0-a2c3-47ec-a2d8-05f41bfbde51/b77b0536-9772-4ade-afca-d30de75d9f1b/3000x3000/paresh-gajria.jpg?aid=rss_feed", "summary": "The episode examines the ethics and economics of drug pricing through two case studies: Zaltrap, a $11,000/month cancer drug offering 42 additional days of life, and Sovaldi, a $84,000 hepatitis C cure with 95% efficacy. It presents data on insurance dynamics, out-of-pocket costs, and systemic strain, showing how high drug prices force rationing. Memorial Sloan Kettering\u2019s public boycott of Zaltrap led to a 50% price cut, demonstrating rare institutional pushback.", "key_takeaways": ["Drug pricing often lacks correlation with clinical benefit\u2014Zaltrap cost $11,000/month for a 42-day survival gain, double the price of an equally effective alternative.", "Insurance structures amplify individual drug costs across populations: one $100,000 treatment depletes funds for 1,000 insured members.", "High-efficacy, high-cost cures like Sovaldi ($84,000 for 12 weeks) force states to ration treatment based on disease severity, delaying care until patients are sicker."], "best_for": ["healthcare professionals", "health policy analysts", "patients navigating high-cost treatments"], "why_listen": "It reveals how drug pricing decouples from medical value, with real-world data and institutional resistance that reshaped a pharmaceutical company\u2019s pricing strategy.", "verdict": "must_listen", "guests": [], "entities": {}, "quotes": [], "chapters": [], "overall_score": 89.0, "score_breakdown": {"clarity": 95.0, "originality": 87.0, "actionability": 85.0, "technical_depth": 88.0, "information_density": 90.0}, "score_evidence": {"clarity": "The survival difference between the people who got Zaltrap and the people who didn't was one point four months or forty two days.", "originality": "Memorial Sloan Kettering, they decide to boycott this drug. That is that I mean, I'm just stopping you because when you guys made that decision, was that that feels like a big deal.", "actionability": "We decided to write the op ed piece in the New York Times. They write an op ed in the Times that basically says, look. This is crazy.", "technical_depth": "We walked through the out of pocket expenses for Medicare beneficiaries. Medicare beneficiaries, if they don't have additional insurance, 20\u00a2 of every dollar they pay out of pocket.", "information_density": "Seventy thousand people in the country were treated, and it had a ninety five percent rate of cure. In other words Holy cow. The virus was eradicated."}, "score_reasoning": {}, "scoring_confidence": 0.95, "transcript_available": true, "transcript_chars": 68510, "transcript_provider": "deepgram"}